Johnson & Johnson Shs (JNJ) Price & Analysis

6 Followers

JNJ Stock Chart & Stats

C$32.93

-C$0.25(-0.75%)

Jul 10, 2026

―

Day’s Range― - ―

52-Week RangeC$26.00 - C$34.52

Previous CloseN/A

VolumeN/A

Average Volume (3M)N/A

Market Cap

C$884.08B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)28.6

Beta0.39

Next Earnings

Jul 15, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.29

Shares Outstanding2,407,217,000

10 Day Avg. VolumeN/A

30 Day Avg. VolumeN/A

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Johnson & Johnson Shs News

Federal health role nominee has record of vaccine skepticism, Stat News reports

Sean Kaufman, who has been nominated to be Assistant Secretary for Preparedness and Response for the Trump administration,...

12h ago

AZN

EBS

Johnson & Johnson price target raised to $263 from $254 at BofA

BofA raised the firm’s price target on Johnson & Johnson to $263 from $254 and keeps a Neutral...

22h ago

JNJ

Johnson & Johnson announces FDA approval for THERMOCOOL SMARTTOUCH SF

Johnson & Johnson announced that the U.S. Food and Drug Administration approved the Dual Energy THERMOCOOL SMARTTOUCH SF...

3d ago

JNJ

Johnson & Johnson price target raised to $284 from $283 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Johnson & Johnson to $284 from $283...

3d ago

JNJ

Johnson & Johnson price target raised to $298 from $285 at Citi

Citi raised the firm’s price target on Johnson & Johnson to $298 from $285 and keeps a Buy...

3d ago

JNJ

Protagonist Therapeutics price target raised to $145 from $121 at Truist

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $145 from $121 and keeps a Buy...

4d ago

JNJ

PTGX

Johnson & Johnson price target raised to $290 from $280 at HSBC

HSBC raised the firm’s price target on Johnson & Johnson to $290 from $280 and keeps a Buy...

5d ago

JNJ

AI Daily: Amazon’s AWS commits $1B toward new unit

Catch up on the top artificial intelligence news and commentary by Wall Street analysts on publicly traded companies...

11d ago

AZN

BMY

Anthropic takes aim at pharma industry with Claude Science, STAT reports

Anthropic has launched Claude Science, a version of its AI tailored for scientific and pharmaceutical research, marking a...

11d ago

AZN

BMY

Johnson & Johnson presents new Imaavy data at EAN 2026 Congress

Johnson & Johnson announced new data across 12 abstracts at the European Academy of Neurology 2026 Congress that...

15d ago

JNJ

J&J Oncology Outlook Largely Priced In: Gerberry Reiterates Hold Rating with Unchanged $254 Price Target

Johnson & Johnson, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry...

1M ago

JNJ

Underappreciated Autoimmune Franchise Potential Keeps Johnson & Johnson at Buy with Unchanged $275 Price Target

Analyst Asad Haider from Goldman Sachs maintained a Buy rating on Johnson & Johnson and keeping the price...

2M ago

JNJ

Johnson & Johnson: Diversified Growth, Robust Pipeline, and Attractive Risk‑Reward Support Buy Rating

Analyst Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson and keeping the price...

3M ago

JNJ

Early Icotyde Approval Strengthens Johnson & Johnson’s Immunology Growth Outlook and Multi‑Billion‑Dollar Potential

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Johnson & Johnson, retaining the price target...

4M ago

JNJ

JNJ FAQ

What was Johnson & Johnson Shs’s price range in the past 12 months?

Johnson & Johnson Shs lowest stock price was C$26.00 and its highest was C$34.52 in the past 12 months.

What is Johnson & Johnson Shs’s market cap?

Johnson & Johnson Shs’s market cap is C$884.08B.

When is Johnson & Johnson Shs’s upcoming earnings report date?

Johnson & Johnson Shs’s upcoming earnings report date is Jul 15, 2026 which is in 4 days.

How were Johnson & Johnson Shs’s earnings last quarter?

Johnson & Johnson Shs released its earnings results on Apr 14, 2026. The company reported C$0.286 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.286.

Is Johnson & Johnson Shs overvalued?

According to Wall Street analysts Johnson & Johnson Shs’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Johnson & Johnson Shs pay dividends?

Johnson & Johnson Shs does not currently pay dividends.

What is Johnson & Johnson Shs’s EPS estimate?

Johnson & Johnson Shs’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Johnson & Johnson Shs have?

Johnson & Johnson Shs has 2,407,217,000 shares outstanding.

What happened to Johnson & Johnson Shs’s price movement after its last earnings report?

Johnson & Johnson Shs reported an EPS of C$0.286 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.174%.

Which hedge fund is a major shareholder of Johnson & Johnson Shs?

Currently, no hedge funds are holding shares in TSE:JNJ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology